TreatSMA

TreatSMA arranges meeting with MPs to follow up Jacob Rees-Mogg’s call for debate.

TreatSMA are asking for those not eligible for Spinraza, to contact MPs and get involved in the debate.

Dear Community,
We are acutely aware that some of you are still not eligible for treatment and therefore we continue to explore various avenues to change that.
On the back of the appeal and #eggonyourface campaign we now continue to engage with numerous MPs to discuss this situation. In the next few days we will be in the Houses of Parliament meeting with politicians. We hope to gain their support for change. If you are one of the people who is not eligible for Spinraza please contact your MP and say that you’d like for TreatSMA to come and meet them in London on your behalf.
Thank you.
TreatSMA team.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more